Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 457 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR A Remarkable Group of Patients with Haematological Disorders with No or... December 15, 2021 Pediatric MATCH Study Finds More Targetable Genetic Changes than Expected May 16, 2019 Adding Chemotherapy to Radiotherapy Not Associated with Improved OS for Patients... April 7, 2025 New on NCI’s Websites for November 2021 November 5, 2021 Load more HOT NEWS COVID-19 Takes the Life of a Widowed Mother of 6 Who... FDA Approves Relugolix for Advanced Prostate Cancer Husband Turns Wife’s Inspiring Poem for Her Daughters into a Book... Working Together to Choose a Cancer Treatment Plan: A Caregiver’s Perspective
